It also overcomes the challenges associated with the lack of specificity in anti-CD3 stimulation, enabling up to a 1000-fold expansion of antigen-specific CD8+ T cells from patients with melanoma in 2 weeks (27). The gene discussed is CD8A; the disease is melanoma.